Amlan International Brings Gut Health and Feed Efficiency Innovation to IPPE 2026

Rhea-AI Summary

Amlan International (NYSE: ODC) will exhibit at the International Production & Processing Expo (IPPE) 2026, January 27–29, at the Georgia World Congress Center in Atlanta. Visit booth B6041 to learn about mineral-based feed additives that target gut health, feed efficiency and profitability in antibiotic-free poultry systems. Amlan will highlight Varium, a natural alternative to antibiotic growth promoters supported by over a decade of research for improving gut integrity, reducing intestinal damage under disease challenge, and improving nutrient utilization.

Dr. Aldo Rossi will deliver a TECHTalk on Jan. 28 at 11:00 a.m. EST titled "Guarding Intestinal Health from Clostridial Challenges Through Innovative Feed Programs." Amlan staff will discuss research, field results and commercial applications.

News Market Reaction

+3.61%

1 alert

+3.61% News Effect

On the day this news was published, ODC gained 3.61%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

IPPE 2026 dates: January 27–29, 2026 Feed cost share: 70% of total production costs Company expertise: 80 years +1 more

4 metrics

IPPE 2026 dates January 27–29, 2026 International Production & Processing Expo in Atlanta

Feed cost share 70% of total production costs Share of feed in poultry production costs

Company expertise 80 years Oil-Dri mineral science experience leveraged by Amlan

TECHTalk time 11:00 a.m. EST, January 28 Dr. Rossi’s TECHTalk at IPPE 2026

Market Reality Check

Price: $64.55 Vol: Volume 71,234 is below 20...

normal vol

$64.55 Last Close

Volume Volume 71,234 is below 20-day average 89,602 (relative activity 0.8x). normal

Technical Shares at $49.12 trade below the 200-day MA $54.55, 29.58% under the $69.755 52-week high and above the $40.66 low.

Peers on Argus

ODC is up 2.33% while peers like SCL (+4.25%), ECVT (+3.45%), KRO (+5.78%) and O...

ODC is up 2.33% while peers like SCL (+4.25%), ECVT (+3.45%), KRO (+5.78%) and OEC (+5.66%) also rose, but no peers appeared in the momentum scanner, indicating a more stock-specific move than a confirmed sector rotation.

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	Dividend increase	Positive	+3.2%	Board approved a 14% increase in quarterly cash dividends.
Dec 08	Earnings results	Neutral	-1.4%	Reported Q1 FY2026 results with strong income but YoY declines.
Dec 03	Forbes recognition	Positive	-2.3%	Named to Forbes’ 2026 list of America’s Most Successful Small-Caps.
Dec 01	Management hire	Positive	+0.9%	Appointed APAC Technical Service Director to support Amlan growth.
Oct 28	Earnings webcast	Neutral	-2.6%	Scheduled Q1 FY2026 earnings discussion and 2025 annual meeting webcast.

Pattern Detected

Recent ODC news has shown mixed price responses, with some positive corporate updates rewarded and others, like recognition accolades, seeing negative next-day moves.

Recent Company History

Over the past few months, Oil-Dri reported Q1 FY2026 results with $120.5M in net sales and $15.5M in net income, described as its second-highest quarterly net income, alongside some year-over-year margin and sales pressure. The company was again named to Forbes’ 2026 Most Successful Small-Cap list and announced leadership expansion at Amlan for APAC growth. A 14% dividend increase underscored a long dividend track record. Today’s Amlan IPPE 2026 presence continues that narrative of focusing on animal health and B2B growth.

Market Pulse Summary

This announcement highlights Amlan’s continued emphasis on gut health and feed-efficiency solutions ...

Analysis

This announcement highlights Amlan’s continued emphasis on gut health and feed-efficiency solutions showcased at IPPE 2026, reinforcing Oil-Dri’s 80-year mineral-science heritage and ongoing focus on antibiotic-free poultry production. Within recent months, ODC reported strong but moderating Q1 FY2026 earnings, increased its dividend by 14%, and expanded Amlan leadership in APAC. Investors following this news may track future Amlan sales trends, margin performance, and adoption of products like Varium in commercial poultry systems.

Key Terms

antibiotic growth promoters, subclinical disease, pathogenic bacteria, biotoxins, +3 more

7 terms

antibiotic growth promoters medical

"As poultry producers continue to move away from antibiotic growth promoters,"

Antibiotic growth promoters are low-dose antibiotics added to animal feed to help livestock grow faster and use feed more efficiently, similar to a dietary supplement that boosts performance. They matter to investors because regulators, retailers and consumers increasingly restrict or reject these additives for health and resistance concerns, which can change costs, market access and reputational risk for food producers and related companies.

subclinical disease medical

"Subclinical disease, pathogenic bacteria and biotoxins can persist even in flocks"

Subclinical disease is a health condition that exists in the body but does not cause noticeable symptoms and is usually found only through medical tests or screening. For investors, it matters because these hidden cases can change the size of the addressable market, affect clinical trial outcomes and regulatory decisions, and influence demand for diagnostics or treatments—much like an iceberg whose bulk is unseen but alters the outlook for related products and revenues.

pathogenic bacteria medical

"Subclinical disease, pathogenic bacteria and biotoxins can persist even in flocks"

Pathogenic bacteria are microscopic germs that cause infections or disease in people, animals, or plants—think of them as harmful intruders that disrupt normal health. For investors, they matter because outbreaks, contamination or treatment-resistant strains can drive demand for diagnostics, vaccines and antibiotics, trigger product recalls or regulatory action, and affect healthcare costs, company sales and legal liabilities.

biotoxins medical

"Subclinical disease, pathogenic bacteria and biotoxins can persist even in flocks"

Biotoxins are poisonous substances produced by living organisms—such as bacteria, algae, plants or animals—that can contaminate food, water, drugs or environments and harm humans or animals. For investors they matter because outbreaks, contamination or regulatory action tied to biotoxins can trigger product recalls, legal liability, cleanup costs, changes in demand, or new market opportunities for testing and remediation; think of them like biological contaminants that can suddenly make a product unsafe and costly to fix.

gut integrity medical

"subclinical disease, pathogenic bacteria and biotoxins... compromising gut integrity, impairing nutrient"

Gut integrity is the condition of the digestive tract’s lining and its ability to absorb nutrients while blocking harmful microbes and toxins. Investors care because products, drugs or foods that improve or harm gut integrity can change market demand, clinical trial outcomes, regulatory decisions and operational costs—like a fence around a garden: a strong fence keeps pests out and crops healthy, while a broken one lets problems spread and reduces yield.

immune function medical

"Designed to support gut integrity, immune function and resilience to pathogenic challenges,"

The body’s ability to detect, respond to and remove threats like infections, cancers or foreign substances; think of it like a building’s security system that senses intruders and dispatches guards. Investors watch measures of immune function because they influence the success of vaccines, drugs and diagnostics, affect clinical trial outcomes and regulatory decisions, and therefore can change sales forecasts, risk assessments and company valuations.

clostridial medical

"Guarding Intestinal Health from Clostridial Challenges Through Innovative Feed Programs."

Relating to Clostridium, a group of bacteria that can cause infections or produce powerful toxins; the term is used to describe diseases, laboratory tests, vaccines, diagnostics, or treatments that involve these organisms. For investors, 'clostridial' flags medical and regulatory issues—safety risks, approval hurdles, liability exposure, and potential market demand for products that prevent, detect, or treat infections caused by these bacteria, much like a product label that names the specific threat it targets.

AI-generated analysis. Not financial advice.

CHICAGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Amlan^® International, a global leader in mineral-based feed additives, will exhibit at the International Production & Processing Expo (IPPE) 2026, taking place January 27–29 at the Georgia World Congress Center in Atlanta, Georgia. Attendees are invited to visit Amlan at booth B6041 to learn how science-backed solutions can help optimize gut health, feed efficiency and profitability in antibiotic-free poultry production.

As poultry producers continue to move away from antibiotic growth promoters, maintaining profitability under real-world production pressure has become increasingly complex. With feed representing up to 70% of total production costs, feed efficiency is a primary driver of economic performance. Subclinical disease, pathogenic bacteria and biotoxins can persist even in flocks that appear healthy, quietly eroding margins by suppressing feed intake, compromising gut integrity, impairing nutrient utilization and diverting energy away from growth.

“Today’s producers are facing unprecedented pressure to perform without antibiotics while still protecting margins,” said Dr. Wade Robey, President of Amlan International. “Our focus is on delivering proven, natural solutions that help customers maintain consistent performance when it matters most — in real production environments, not just controlled trials.”

During IPPE 2026, Amlan will spotlight how Varium^®, a natural alternative to antibiotic growth promoters, helps improve feed efficiency and performance in antibiotic-free systems. Designed to support gut integrity, immune function and resilience to pathogenic challenges, Varium is backed by more than a decade of research demonstrating measurable improvements in gut health, reduced intestinal damage under disease challenge and more consistent performance under commercial stressors. By safeguarding gut function, nutrients are more effectively utilized for growth and feed conversion — supporting stronger returns on feed investment.

“Profitability depends on sustaining peak performance under the greatest pressure,” said Dr. Aldo Rossi, Director of Veterinary Services, Amlan International. “Safeguarding gut health and optimizing feed efficiency are critical strategies for protecting margins in poultry production.”

In addition to his presence at the Amlan booth, Dr. Rossi will deliver a TECHTalk on Wednesday, January 28, at 11:00 a.m. EST, titled “Guarding Intestinal Health from Clostridial Challenges Through Innovative Feed Programs.” His presentation will explore practical strategies for protecting intestinal integrity and sustaining performance in the face of increasing clostridial pressure in modern poultry systems.

Amlan’s team will be available throughout the expo to discuss current research, field results and real-world applications for building resilience into poultry production programs.

Company Information

Amlan is the animal health business of Oil-Dri Corporation of America, a leading global manufacturer and marketer of sorbent minerals. Leveraging over 80 years of expertise in mineral science, Oil-Dri Corporation of America, doing business as “Amlan International,” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives worldwide. Product availability may vary by country; associated claims do not constitute medical claims and may differ based on government requirements.

Contact:
Reagan Culbertson, Vice President of Strategic Marketing, B2B
Reagan.culbertson@amlan.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e53dad1e-d2bd-41c2-99d2-6f97c60cde4e

FAQ

When and where will Amlan International (ODC) exhibit at IPPE 2026?

Amlan will exhibit at IPPE 2026 in Atlanta, January 27–29, at the Georgia World Congress Center, booth B6041.

What is Varium and how does it help poultry producers using ODC stock?

Varium is a natural feed additive promoted to support gut integrity and improve feed efficiency in antibiotic-free poultry systems, backed by over a decade of research.

When is Dr. Aldo Rossi’s TECHTalk at IPPE 2026 and what is the topic?

Dr. Aldo Rossi will present on January 28 at 11:00 a.m. EST on strategies to protect intestinal integrity from clostridial challenges.

How does Amlan say Varium improves feed efficiency and profitability?

Amlan states Varium helps safeguard gut function so nutrients are better utilized for growth, which can support improved feed conversion and returns on feed investment.

Can investors find Amlan product availability and contact information for follow-up?

Amlan notes product availability varies by country and provides a corporate contact for strategic marketing inquiries; visit booth B6041 or contact Reagan Culbertson for details.